Next-Generation Intratumoral Technology Targets Diffuse Intrinsic Pontine Glioma
Investigational New Drug Enabling Studies Are Underway, With a Planned Clinical Trial to Launch Late 2026
FORT WORTH, Texas, Dec. 11, 2025 — , a private clinical-stage oncology firm, is pleased to announce its drug development initiative focused on transforming the treatment of diffuse intrinsic pontine glioma (DIPG), an aggressive and highly fatal pediatric brainstem tumor. The company is developing Large Surface Area Microparticle (LSAM) Cisplatin for stereotactic intratumoral (IT) use in this initial indication.
Plans for Pediatric Clinical Trials
NanOlogy is completing Investigational New Drug (IND) enabling studies required by the U.S. Food and Drug Administration (FDA). Once these studies are done, the company plans to submit an IND application for LSAM-Cisplatin to treat malignant brain tumors, including DIPG. Subject to FDA approval to proceed, NanOlogy aims to launch a clinical trial in late 2026 to evaluate the safety and response of stereotactic IT delivery of LSAM-Cisplatin in children diagnosed with DIPG. According to DIPG.org, DIPG affects 150–300 children each year in the United States, with a median survival of less than one year. Current treatments like radiation therapy may slow progression but almost always fail to deliver long-term survival. NanOlogy is also exploring future opportunities to expand LSAM-Cisplatin’s use to other brain and solid tumors.
The Promise of LSAM-Cisplatin in DIPG
Lab research has shown cisplatin kills DIPG tumors by binding to DNA and disrupting cell replication, leading to cell death. Unfortunately, current systemically administered cisplatin formulations are linked to numerous severe side effects throughout the body. Additionally, cisplatin does not cross the blood-brain barrier effectively, limiting its efficacy in brain tumors and making systemic cisplatin a suboptimal treatment for DIPG.
“We believe NanOlogy’s innovative LSAM-Cisplatin investigational drug—designed for intratumoral administration—can overcome the limitations of current treatments through highly targeted drug delivery into the tumor, continuous drug release, and minimal systemic toxicity,” said H. Paul Dorman, founder and chairman of NanOlogy. “Advancements in minimally invasive surgical techniques and imaging now allow local delivery of LSAMs to solid tumors virtually anywhere in the body, including the brain. We’re excited to advance IT LSAM-Cisplatin for DIPG and explore the hope it may hold for children and families facing this devastating disease.”
About NanOlogy
NanOlogy, LLC () is a private clinical-stage oncology company developing treatments for solid tumors using drugs optimized for intratumoral delivery to improve response with minimal to no systemic toxicity. Enabled by CritiTech Particle Engineering Solutions’ Purcision
technology platform, NanOlogy produces Large Surface Area Microparticles (LSAMs) of pure drug for direct local delivery, addressing issues of systemic toxicity and tumor bioavailability. NanOlogy have advanced LSAM investigational drugs in multiple solid tumors, including pancreatic, lung, bladder, peritoneal, ovarian, prostate, and dermal cancers. The Purcision platform’s feasibility has been established for taxanes, platins, tyrosine kinase inhibitors, poly (ADP-ribose) polymerase inhibitors, and other agents. The investigational drugs are covered by composition-of-matter patents issued in the United States and other major global jurisdictions—including Canada, Europe, Japan, China, South Korea, Australia, and India—which form the foundation of an extensive intellectual property portfolio with over 100 issued patents protecting NanOlogy’s investigational drugs, formulations, methods, and technology.
Media Contact
Marc Iacobucci
1-817-916-2247
SOURCE NanOlogy, LLC